Delcath Systems (DCTH) to Announce Earnings on Thursday

Delcath Systems (NASDAQ:DCTH) is anticipated to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.09) per share and revenue of $26.2590 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.07. Delcath Systems had a return on equity of 0.51% and a net margin of 0.62%.The firm had revenue of $24.99 million for the quarter, compared to the consensus estimate of $23.51 million. On average, analysts expect Delcath Systems to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Delcath Systems Trading Up 0.8%

DCTH opened at $13.14 on Wednesday. The stock’s 50-day moving average price is $12.14 and its 200 day moving average price is $10.79. Delcath Systems has a 12-month low of $8.12 and a 12-month high of $13.74. The firm has a market cap of $453.59 million, a price-to-earnings ratio of 1,314.00 and a beta of 0.52.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of DCTH. Deutsche Bank AG grew its stake in Delcath Systems by 5.4% during the 4th quarter. Deutsche Bank AG now owns 24,162 shares of the company’s stock worth $244,000 after purchasing an additional 1,248 shares in the last quarter. California State Teachers Retirement System acquired a new stake in Delcath Systems in the 2nd quarter valued at about $26,000. Intech Investment Management LLC boosted its stake in shares of Delcath Systems by 13.1% in the 4th quarter. Intech Investment Management LLC now owns 17,595 shares of the company’s stock valued at $178,000 after buying an additional 2,035 shares during the period. AWM Investment Company Inc. boosted its stake in shares of Delcath Systems by 3.9% in the 4th quarter. AWM Investment Company Inc. now owns 60,000 shares of the company’s stock valued at $606,000 after buying an additional 2,279 shares during the period. Finally, Russell Investments Group Ltd. acquired a new position in shares of Delcath Systems during the third quarter worth about $29,000. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on DCTH. BTIG Research reiterated a “buy” rating and set a $17.00 price target on shares of Delcath Systems in a research note on Monday, July 13th. Weiss Ratings raised shares of Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Finally, Zacks Research upgraded shares of Delcath Systems from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $22.17.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.